12 Health Care Stocks Moving In Monday's Pre-Market Session - Chemomab Therapeutics (NASDAQ:CMMB), F-star Therapeutics (NASDAQ:FSTX), Dermata Therapeutics (NASDAQ:DRMA), Bluejay Diagnostics (NASDAQ:BJDX), TransCode Therapeutics (NASDAQ:RNAZ), Cyclo Therapeutics (NASDAQ:CYTH), Kala Pharmaceuticals (NASDAQ:KALA), Hoth Therapeutics (NASDAQ:HOTH), Unity Biotechnology (NASDAQ:UBX), Palisade Bio (NASDAQ:PALI), Allarity Therapeutics (NASDAQ:ALLR), SILO Pharma (NASDAQ:SILO)

Gainers

  • Dermata Therapeutics DRMA stock increased by 149.3% to $0.5 during Monday’s pre-market session. The company’s market cap stands at $6.0 million.
  • Allarity Therapeutics ALLR shares moved upwards by 80.66% to $0.5. The company’s market cap stands at $7.2 million.
  • SILO Pharma SILO stock rose 45.61% to $4.98. The market value of their outstanding shares is at $15.6 million.
  • Kala Pharmaceuticals KALA stock increased by 40.9% to $35.0. The market value of their outstanding shares is at $55.8 million.
  • F-star Therapeutics FSTX stock increased by 38.14% to $5.65. The market value of their outstanding shares is at $124.1 million.
  • Palisade Bio PALI stock rose 31.05% to $4.22. The market value of their outstanding shares is at $6.0 million.

Losers

  • Hoth Therapeutics HOTH stock fell 30.2% to $7.48 during Monday’s pre-market session. The market value of their outstanding shares is at $9.7 million.
  • Bluejay Diagnostics BJDX stock decreased by 14.05% to $0.33. The market value of their outstanding shares is at $6.7 million.
  • Chemomab Therapeutics CMMB stock decreased by 13.8% to $2.5. The company’s market cap stands at $28.8 million.
  • TransCode Therapeutics RNAZ shares decreased by 12.3% to $0.5. The company’s market cap stands at $6.4 million.
  • Unity Biotechnology UBX shares fell 11.95% to $2.42. The company’s market cap stands at $34.3 million.
  • Cyclo Therapeutics CYTH shares decreased by 11.81% to $1.27. The company’s market cap stands at $10.7 million.
    See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.



Image and article originally from www.benzinga.com. Read the original article here.